A New Startup Wants to Use Crispr to Diagnose Disease

Published Apr 27, 2018, 7:12 AM
In 2011, biologists Jennifer Doudna and Emmanuelle Charpentier published a landmark paper introducing the world to Crispr. The arcane family of bacterial proteins had a talent for precisely snipping DNA, and one of them—Cas9—has since inspired a billion-dollar boom in biotech investment. Clinical trials using Cas9 clippers to fix genetic defects are just beginning, so it will be years before Crispr-based cures could potentially reach the world.

WIRED Science

Get in-depth coverage of current and future trends in technology, and how they are shaping business, 
Social links
Follow podcast
Recent clips
Browse 2,105 clip(s)